Plaque Psoriasis

Addition of apremilast to a regimen of topical corticosteroids was safe and effective in patients with moderate plaque-type psoriasis.

A fixed-dose combination lotion comprised of halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) is more effective for treating moderate-to-severe plaque psoriasis than either component alone.

Researchers completed 2 post hoc analyses of large, double-blind trials examining the efficacy of HP/TAZ combination therapy for clinically meaningful outcomes.

The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.

Lexette (halobetasol propionate) foam 0.05% has been made available for patients 18 years of age and older for the topical treatment of plaque psoriasis.

In the ECLIPSE study (N=1048), patients were randomized to receive guselkumab 100mg at weeks 0, 4, and 12 followed by every 8-week dosing or secukinumab 300mg at weeks 0, 1, 2 3, 4 followed by every 4-week dosing.

The ability of secukinumab vs placebo to clear nail psoriasis was evaluated using the Nail Psoriasis Severity Index.

Investigators evaluated the effect of ixekizumab withdrawal and retreatment in Japanese patients with plaque psoriasis in this single-arm open-label phase 3 study.

The approval was supported by data from 2 prospective, multicenter, randomized, double-blind clinical trials.